Clinical and experimental aspects of novel antidiabetic therapies. From the gut and the kidney towards the cardiovascular system: the last ten years of the antidiabetic drugs.

Thursday, October 26th / 14.00-16.00
119 A matter of safety?
Annalisa Capuano
192 The EMPAREG-OUTCOME study and the dilemma of the cardiovascular protection
Edoardo Mannucci
197 The point of view of the cardiologist
Pasquale Perrone Filardi
198 The point of view of the diabetologist
Angelo Avogaro
210 What the research tells us: mechanistic hypotheses of empaglifozin protection
Raffaele Coppini
212 Wrap-up/conclusion
Giorgio Sesti